Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight
In brief
Positive Phase 3 cancer trial data for intismeran led to a sharp intraday rally in mRNA stocks, but after‑hours trading saw a pullback as investors took profits or reassessed upside.